Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47 30/06/2025

106,12 USD (-0,73%)

(-0,73%) 30/06/2025

Grafiek Jazz Pharmaceuticals plc

Grafiek Jazz Pharmaceuticals plc

1 dag1d -0,73%
1 week1w -0,60%
1 maand1m -1,80%
3 maanden3m -14,52%
6 maanden6m -13,70%
1 jaar1j -0,33%
5 jaar5j -3,82%

Jazz Pharmaceuticals plc in het nieuws

Toon enkel gratis nieuws

6 mei 2025 · Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance · Persbericht

30 april 2025 · Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference · Persbericht

25 april 2025 · Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer · Persbericht

23 april 2025 · Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma · Persbericht

22 april 2025 · Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 · Persbericht

21 april 2025 · Jazz Pharmaceuticals Completes Acquisition of Chimerix · Persbericht

26 maart 2025 · Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference · Persbericht

19 maart 2025 · Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting · Persbericht

5 maart 2025 · Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio · Persbericht

9 september 2024 · Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024 · Persbericht

Profiel Jazz Pharmaceuticals plc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

CEO: Bruce Cozadd

Werknemers: 3.199

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe